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Abstract 
Background: Earlier studies by our group have demonstrated that a transgenic animal engineered to express Tie2 
under the control of the Tie2 promoter produced animals with a scaly skin phenotype that recapitulated many of the 
hallmarks of atopic dermatitis (AT-Derm). To test the hypothesis that this model of AT-Derm is driven by dysregulated 
Tie2-signalling, we have bred AT-Derm transgenic (TG) animals with TG-animals engineered to overexpress Angi-
opoietin-1 or -2, the cognate Tie2 ligands. These two ligands act to antagonize one another in a context-dependent 
manner. To further evaluate the role of Ang1-driven-Tie2 signalling, we examined the ability of Vasculotide, an Ang1-
mimetic, to modulate the AT-Derm phenotype.
Results: AT-Derm+Ang2 animals exhibited an accentuated phenotype, whereas AT-Derm+Ang1 presented with a 
markedly reduced skin disease, similarly VT-treated AT-Derm animals present with a clear decrease in the skin pheno-
type. Moreover, a decrease in several important inflammatory cytokines and a decrease in the number of eosinophils 
was noted in VT-treated animals. Bone marrow differentiation in the presence of VT produced fewer CFU-G colonies, 
further supporting a role for Tie2-signalling in eosinophil development. Importantly, we demonstrate activation of 
Tie2, the VT-target, in lung tissue from naïve animals treated with increasing amounts of VT.
Conclusions: The AT-Derm phenotype in these animals is driven through dysregulation of Tie2 receptor signalling 
and is augmented by supplemental Ang2-dependent stimulation. Overexpression of Ang1 or treatment with VT 
produced a similar amelioration of the phenotype supporting the contention that VT and Ang1 have a similar mecha-
nism of action on the Tie2 receptor and can both counteract the signalling driven by Ang2. Our results also support 
a possible role for Tie2-signalling in the development of eosinophilic diseases and that activation of Tie2 may directly 
or indirectly modulate the differentiation of eosinophils, which express Tie2. In summary, these data support the 
hypothesis that this AT-Derm mouse model is driven by dysregulation of the Tie2 signalling pathway and increased 
Ang2 levels can aggravate it, whereas it can be reversed by either Ang1-overexpression or VT treatment. Moreover, 
our data supports the contention that VT acts as an Angiopoietin-1 mimetic and may provide a novel entry point for 
Tie2-agonist-based therapies for atopic diseases.
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Findings
A Tie2‑driven model of AT‑Derm
In two earlier publications, we describe the genera-
tion and characterization of a doxycycline-controlled 
transgenic mouse [1, 2] that presents with many of the 
physical hallmarks of psoriasis, however more extensive 
analysis of cytokine production and cellular infiltrate 
into the skin revealed that this model more accurately 
reflects AT-Derm [2]. Thus, this model provides an entry 
point into investigating some of the early factors that 
control the appearance and propagation of AT-Derm. 
In this study, we set out to test the hypothesis that this 
model of AT-Derm was driven by dysregulation of Tie2-
signalling by either of the Tie2-cognate ligands, Ang1 or 
Ang2. In order to investigate the function of Ang1 and 
Ang2 in vivo, we engineered several transgenic lines that 
contained the Tet-responsive element upstream of either 
Ang1 or Ang2 (Fig.  1a) [3, 4]. These animals provided 
a way to regulate the overexpression of either of these 
ligands with doxycycline when mated with transgenic 
animals expressing the tetracycline-responsive transac-
tivator, tTA. AT-Derm animals, which contain the two 
transgenes, pTek-tTA & tetos-Tie2 (Fig.  1a), that drive 
the AT-Derm phenotype, were bred to express a third 
transgene, pTetos-Ang1 and now present with an ame-
lioration of the phenotype (Fig. 1b), whereas AT-Derm-
Ang2 animals exhibit a much more severe phenotype. 
These AT-Derm-Ang2 animals present with increased 
erythema around the eyes, ears and snout and increased 
micro-hemorrhages in the ears (Fig.  1c). Importantly, 
the Ang2-accentuated phenotype is not observed in the 
absence of the Tie2-expressing transgene (tetos-Tie2) 
Fig. 1 Depiction of the transgenes used in this study and the AT-Derm phenotype. a Diagram of the engineered transgenes. The animals express-
ing pTek-tTA and pTetos-Tie2 together develop the AT-Derm phenotype as seen in 7 day old mice (right) compared to a wildtype littermate (left). 
The scaly skin phenotype of the AT-Derm animal is clearly evident. The Ang1 and Ang2 responder transgenes are also depicted to the right. b Gross 
phenotypic improvement is noted when experimental AT-Derm mice are crossed to the Ang1 pTetOS-Ang1 mice, triple transgenic (pTek-tTA: pTetOS-
Tie2: pTetOS-Ang1). Superficially, these effects are seen by a decrease in erythema around the nose and eyes. Also noted is a reduction in ear micro 
haemorrhages and tail scaly plaque formation (not shown). c AT-Derm Ang2-expressing triple transgenic mice present with increased erythema, 
micro haemorrhages and tail plaque (not shown). d Wild type and the Ang2-double transgenic (pTek-tTA: pTetOS-Ang2) exhibit no phenotype, 
whereas, the AT-Derm present with the characteristic erythema around the nose and eyes, which is much more accentuated in the AT-Derm+Ang2 
triple transgenics. e Same animals as in panel d viewed from above, further illustrating the increased micro-hemorrhages in the ears
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(Fig.  1d, e, pTek-tTA+Ang2), demonstrating that the 
AT-Derm phenotype depends upon on the expression of 
Tie2-transgene.
VT‑treatment resolves the AT‑Derm phenotype
The fact that overexpression of Ang1 could reduce the 
severity of the AT-Derm phenotype provided the impe-
tus for us to examine the possibility of substituting Ang1-
overexpression with the Ang1-mimetic, Vasculotide. In 
order to demonstrate that VT engaged Tie2 and led to 
its activation we performed an acute short-term stimula-
tion. In Fig. 2 we demonstrate that VT is able to activate 
Tie2, however this activation decreases as higher concen-
trations of VT are administered. The exact explanation 
for this decreased activation at higher concentrations of 
VT is not completely understood, but may reflect several 
properties of Tie2 signalling, one of which is the ability of 
VT to cluster a sufficient number of receptors on the cell 
surface and if VT is present in excess this ability is lost as 
we drive more monomeric binding of VT to Tie2. Also 
the mode of Tie2 activation is considered quite complex 
and may involve homotypic and heterotypic-interactions 
with other surface molecules [5, 6]. The requirement for 
Tie2 clustering by the Angiopoietins to drive activation 
has been demonstrated by several different groups using 
different methods of clustering Tie2. Such approaches, 
including COMP-Ang1 [7], COMP-Ang2 [8], MAT-Ang1 
[9], Bow-Ang1 [10], all support the notion that the appro-
priate tetrameric or higher order multimeric clustering 
of Tie2 drives Tie2 signaling similar to that of paren-
tal ligand, Ang1. Further supporting a role for cluster-
ing of the Angiopoietins, we have demonstrated using a 
dominant-interfering form of Ang1, CC-Ang1, that both 
in vitro and in vivo the Angiopoietins need to be appro-
priately clustered to activated Tie2 [11]. Taken together 
the results presented here suggests that VT binds to Tie2 
leading to its activation presumably through clustering of 
the receptor on the surface of Tie2-expressing cells.
The ability of VT to activate Tie2 in vivo (Fig. 2) [12–
17] led us to investigate if VT was able to act like Ang1 
in this model and impact the disease phenotype. As we 
have demonstrated in previous papers the AT-Derm ani-
mals have varying degrees of phenotype penetrance, thus 
they are classified as severe or moderate. Mice in each 
of these classes were grouped based on overt skin topol-
ogy. These animals were treated with either PBS or VT 
for 30 days via intraperitoneal injection every third day. 
Prior to the initiation of treatment skin biopsies were 
taken and at the completion of the treatment regime a 
post-treatment biopsy was taken. Thin sections from 
these biopsies were stained with H&E. As first described 
in our earlier manuscripts AT-Derm animals carry many 
of the hallmarks of atopic dermatitis including epidermal 
hyperplasia, increased vascular density and immune cell 
infiltrates [1, 2]. This skin phenotype was not apparent in 
wild type animals, while PBS (vehicle) treated AT-Derm 
animals did present the skin phenotype. Significantly, the 
skin from VT-treated AT-Derm animals closely resem-
bled the tissue taken from WT animals (Fig.  3). Thick-
ening of the epidermis was no longer evident and there 
was a decrease in the vessel and immune cell density. The 
resolution of the AT-Derm skin phenotype mirrored that 
of AT-Derm-Ang1 animals supporting the notion that 
VT, like Ang1, is able to counteract the Ang2-Tie2 sign-
aling axis and drive an Ang1-Tie2-like signaling pathway. 
Of additional interest is the fact that Ang1 is known to 
engage in signalling through alternate receptors [18, 19], 
however, since VT is only known to bind to Tie2 [12, 16] 
it suggests that virtually all of the AT-Derm phenotype 
is driven through Tie2-signalling and not through these 
alternate Ang-receptors.
VT treatment leads to a decrease in the expression 
of pro‑inflammatory molecules
Immunohistochemical analysis of thin sections taken 
from the animals described above treated with either PBS 
or VT demonstrated that VT treatment resulted in the 
down-regulation of E-selectin, ICAM-1 and VCAM-1 
(Fig. 4a–c). Moreover, this down-regulation of cell adhe-
sion receptor expression was detected in the underlying 
skeletal muscle layer below the affected skin (Fig. 4a–c).
The decrease in the expression of pro-inflammatory 
adhesion molecules led us to investigate the expression 
of key cytokines in the blood of treated animals. Sev-
eral different leukocyte populations play a role in the 
early inflammatory response, including eosinophils. The 
expression of key inflammatory proteins involved in the 
early eosinophilic response (TNF-alpha, IL-9, IL-13, 
MCP-1 and Eotaxin) [20–22] in VT-treated animals was 
decreased in both WT and AT-Derm animals, suggesting 
that VT is able to modulate the inflammatory state both 
in normal and diseased animals (Fig. 5a).
Fig. 2 VT activates Tie2 in vivo. Lung tissue was removed from mice 
treated with different concentrations of VT for 1 h. Animals were 
sacrificed and lung tissue processed by immunoprecipitation for Tie2 
and western blotted with anti-pY and anti-Tie2 antibodies
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The decrease in Eotaxin levels in VT-treated animals 
and the fact that eosinophils express Tie2 and respond 
to Angiopoietin 1 and 2 [23] guided us to examine the 
impact of VT on the number of eosinophils and their 
differentiation [20, 21]. Figure  5b illustrates that VT 
treatments leads to a decrease in the number of eosino-
phils and basophils in both AT-Derm and normal mice. 
These results imply that VT may either directly or indi-
rectly impact the circulating numbers of eosinophils in 
the blood. Moreover, bone marrow extracted from mice 
and cultured in Methocult M3434 media demonstrated 
a VT-dose-dependent decrease in the number of CFU-G 
colonies detected, suggesting that the impact of VT on 
eosinophil numbers in circulation may depend on Tie2-
activity in an early differentiation step.
The cellular target responsible for the noted VT-driven 
decrease in eosinophil number is very difficult to discern 
from these experiments. The obstacles in further defining 
the cell(s) responsible for this effect reside in the fact that 
HSC, eosinophils and ECs all express Tie2 and as such, 
likely all serve as targets for VT-driven activation of Tie2 
[23, 24]. Thus, whether VT-driven Tie2 signalling is hav-
ing a direct or indirect impact on this differentiation pro-
gram has not been resolved. However, the fact that VT 
agonizes Tie2 illustrates that modulation of the Tie2 sign-
aling pathway leads to down-regulation of the inflamma-
tory cascade present in this model of AT Derm.
Conclusions
In this manuscript we demonstrate that experimentally 
induced AT-Derm disease can be modulated through the 
Tie2 receptor with either Ang1-, Ang2- or VT-mediated 
signalling. The impact that VT-driven Tie2 signaling has 
on cytokine production, eosinophil differentiation and 
the expression of pro-inflammatory cell adhesion mol-
ecules on the endothelium illustrates that Tie2 signalling 
Fig. 3 Treatment of AT-Derm animals with VT ameliorates the phenotype. Wildtype or AT-Derm animals with either moderate to severe pheno-
type were treated with VT at 40 µg/kg every 3 days for 30 days. Skin biopsies were taken from the back prior to initiation of treatment and at the 
conclusion of the treatment protocol. Panels correspond to the same animals post- and pre-treatment. Note the epidermal hyperplasia (asterisk) 
and immune cell infiltrate, which is unchanged in animals treated with PBS alone. In contrast, animals receiving VT-treatment presented with an 
epidermal thickness that resembled normal WT animals either treated with PBS or VT
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exerts its anti-inflammatory effects through multiple cel-
lular pathways. Moreover, the fact that VT behaves much 
like Ang1 in these studies further supports the conten-
tion that these two Tie2 agonists display indistinguish-




The transgenic animals used in this study have previously 
been described [1–4, 25, 26]. The housing and treatment 
of animals followed all institutional guidelines and was 
approved by the animal ethics board of SRI.
Fig. 4 VT treatment decreases the expression of important inflammatory cell adhesion proteins. Thin sections prepared from WT and AT-Derm 
animals treated as described above with either PBS or VT were processed for immunohistochemical analysis for the presence of three cell surface 
proteins. a,a’ E-selectin, b,b’ ICAM-1 and c,c’ VCAM-1. Expression of all of these proteins was not detectable or was very low in wt animals. However 
in AT-Derm animals all of these proteins were expressed (arrowheads) and this expression was decreased by VT treatment. VT was effective at 
decreasing the expression of these proteins in the underlying muscular tissue as well (a’, b’, c’)
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Western analysis
Lung tissue lysates were processed for Western analysis 
as previously described [1], with anti-Tie2 and anti-pY 
(4G10) antibodies.
Immunohistochemical analysis
Thin sections from tissue prepared as described [1] were 
stained for the presence of VCAM, ICAM, and E-selectin 
(Pharmagen) using the antibody staining kit from Vector 
and horseradish peroxidase.
VT treatment
Vasculotide is synthesized as described [14, 15, 17]. To 
examine the activation of Tie2 by VT CD-1 mice were 
injected intraperitoneally with indicated amounts of 
VT as described in the figure legend. One hour post 
Fig. 5 VT treatment decreases the expression of Eotaxin and other important inflammatory cytokines and decreases the number of eosinophils 
produced in vitro and in vivo. a Plasma from the animals treated as describe previously analyzed by either cytokine bead array for TNF-α, IL-9, IL-13 
or MCP-1 or by ELISA for Eotaxin. p < 0.05 was considered statistically significant. Statistics were performed as pair-wise analysis with groups shown 
significant differences indicated. b Peripheral blood was drawn from animals treated with vehicle or VT for 30 days. Blood was processed for FACS 
analysis for surface IgE and FITC absorption. The decreased number of basophils and eosinophils in treated normal and AT-Derm mice is clearly 
evident in noted gates, while no effect was seen on neutrophils. c Dissociated bone marrow from CD1 mice was taken and plated in Methocult GF 
M3434 media for 7 days. Hematopoietic colonies were enumerated. A dose dependent, statistically significant reduction in CFU-G numbers was 
noted in response to VT treatment
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VT-treatment animals were sacrificed and lung tissue 
removed for analysis. For AT-Derm studies animals were 
treated with VT at 40 ug/kg every third day for 30 days.
Flow cytometry analysis
Cells from the peripheral blood were processed for the 
presence of eosinophils as described by the vendor BD. 
Blood was processed for FACS analysis for surface IgE 
and FITC absorption.
Cytometric bead array analysis
CBA beads were purchased from BD that were directed 
against TNF-a, IL13, IL9 and MCP-1 and processed as 
described by the vendor. The eotaxin analysis was per-
formed with an eotaxin-specific ELISA as per the ven-
dors protocol (BD). Statistically significant differences are 
indicated (unpaired student t test, where p < 0.05).
Bone marrow culture
Bone marrow was removed from the femur of normal 
CD-1 mice and processed in Methocult as described by 
the vendor (Stemcell Technologies).
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